<DOC>
	<DOCNO>NCT01901289</DOCNO>
	<brief_summary>The Zilver速 PTX速 V Clinical Study post-market clinical trial require US FDA provide continued evaluation safety effectiveness Zilver PTX Drug-Eluting Peripheral Stent treatment narrow femoropopliteal artery .</brief_summary>
	<brief_title>Zilver速 PTX速 V Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Patient sign date informed consent . Patient symptomatic vascular disease native abovetheknee femoropopliteal artery . Patient agree return require followup assessment . Patient &lt; 18 year age . Patient significant stenosis inflow tract successfully treated procedure . Patient lack least one patent vessel runoff &lt; 50 % stenosis throughout course .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>Femoral Artery</keyword>
	<keyword>Popliteal Artery</keyword>
	<keyword>Drug-Eluting Stent</keyword>
</DOC>